Effect of Pioglitazone on HIV-1 Related Lipoatrophy: a Randomized, Double Blind, Placebo-Controlled Trial in 130 Patients
|ClinicalTrials.gov Identifier: NCT00148850|
Recruitment Status : Terminated
First Posted : September 8, 2005
Last Update Posted : October 20, 2005
|Condition or disease||Intervention/treatment||Phase|
|HIV-Associated Lipodystrophy Syndrome HIV Infections||Drug: Pioglitazone||Phase 3|
Lipodystrophy is one of the most frequent treatment side effect in HIV-1 infected patients. This complication can be stigmatizing in some affected patients and lead to reduced adherence to treatment, increased risk of cardiovascular complications and induce insulinoresistance. The pathophysiology of lipodystrophy remains poorly understood. Some antiretroviral drugs could be involved. Therefore, using PPAR G as a therapeutic target with the objective to reverse drug induced lipoatrophy appeared as a promising objective Thiazolidinediones are a new class of insulin sensitizing drugs for the treatment of type 2 diabetes. These PPARG agonist which mainly promote the differentiation of adipocytes, decrease circulating plasma free fatty acids. In non-HIV infected patients this class of drugs decreases intraabdominal fat accumulation and increases subcutaneous fat depot.
Different previous studies were performed with that aim, most of them using rosiglitazone.
We designed a prospective randomized, double blind placebo controlled multicentre study aiming to test the hypothesis that pioglitazone would improve lipoatrophy without deleterious effect on lipid profile in adult subjects receiving antiretroviral therapy.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||130 participants|
|Intervention Model:||Parallel Assignment|
|Official Title:||A Randomized, Phase 3, Double Blind, Multicentre Trial, Evaluating the Effect of Pioglitazone Versus Placebo on Change in Lipoatrophy in HIV- 1 Infected Patients Treated With Stable Antiretroviral Therapy for at Least 6 Months.ANRS 113 LIPIOT Study|
|Study Start Date :||February 2003|
|Estimated Study Completion Date :||October 2004|
- Evolution from inclusion to week 48 of limb fat using DEXA Scan (Dual Energy X-ray Absorptiometry)
- Changes from inclusion to week 48:
- Lipid profile and the glucidic metabolism
- SAT/TAT and VAT/TAT ratios evaluated with scanner
- X ray of L4
- Anthropometric measurements and the quality of life (WHO-QOL-HIV BREF)
- Evaluation of clinical and biological safety
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00148850
|Service des Maladies Infectieuses et Tropicales, Hopital Tenon|
|Paris, France, 75020|
|Principal Investigator:||Willy Rozenbaum, MD||Hopital Tenon Paris|
|Study Chair:||Dominique Costagliola||INSERM U 720|